Phase 1 start for novel triple agonist obesity treatment
Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
Search
Breakthrough Designation granted in US and China
SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Spesolimab prevents GPP flares
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
The impact of A Life in a Day of a patient
A Life in a Day disease simulations are opening our eyes to the patient experience, exposing a surprising knowledge gap and driving change.
Dortmund
The Boehringer Ingelheim microParts GmbH in Dortmund manufactures and advances the technology of the RESPIMAT®.
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
GARC Louis Nel interview on global rabies control
GARC’s Executive Director Professor Louis Nel shares what it takes to fight rabies.
Solidarity with Ukraine
Our company condemns the military aggression against Ukraine and is committed to helping those in need in the longer term with monetary and in kind donations
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
One step further in fighting rabies in Vietnam
A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages.
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
PRRS vaccine discovery for swine
PRRS vaccine, an unexpected scientific discovery. Our team developed the first vaccine against Porcine Reproductive and Respiratory Syndrome in pigs.
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Soaring to save lives
Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
It Takes 2
It Takes 2 people – a patient and a HCP, and 2 tests – a blood and a urine test–to help detect CKD. Early testing can drive earlier diagnosis and treatment.
Boehringer founding sponsor of CKM Health Initiative
Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative
Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Investing in our people University of Medicine Excellence
Almost one thousand of our employees have graduated from a program developed together with Harvard Medical School’s Executive Education.
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.